Clinical Trial Update: A Phase 2 Trial Of The Bruton Tyrosine Kinase Degrader BGB-16673 In Combination With BCL-2 Inhibitor Sonrotoclax For Patients With Treatment-Naive Chronic Lymphocytic Leukemia (CLL) [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating the Bruton's tyrosine kinase degrader BGB-16673 in combination with the BCL-2 inhibitor Sonrotoclax for treatment-naive Chronic Lymph…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• BGB-16673
• Sonrotoclax

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Chronic Lymphocytic Leukemia (CLL) | Phase 2 | Status: NOT_YET_RECRUITING